COVID-19 Boosters Reduce Hospitalization Risk by 29% in Cancer Patients, Large Multi-Center Study Shows
核心洞察
A large retrospective study of over 161,000 cancer (搜索) patients across four major U.S. health systems found that COVID-19 (搜索) booster vaccines reduced hospitalizations and ICU admissions by 29%.
The study showed that boosters prevented one hospitalization or ICU admission for every 150-166 boosted cancer (搜索) patients, demonstrating significant clinical benefit for this vulnerable population.
Despite the proven effectiveness, booster uptake among cancer (搜索) patients remained low, with only 68% receiving the original booster and 38% receiving the updated bivalent booster (搜索).
A comprehensive study analyzing data from over 161,000 cancer (搜索) patients has demonstrated that COVID-19 (搜索) booster vaccines significantly reduce the risk of severe illness in this vulnerable population. The research, published in JAMA Oncology and led by investigators at Cedars-Sinai, found that boosters reduced hospitalizations and intensive care unit admissions by 29%.
The study represents the largest analysis to date of COVID-19 (搜索) booster effectiveness in cancer (搜索) patients, examining real-world data from four major U.S. health systems: Cedars-Sinai, Kaiser Permanente Northern California (搜索), Northwell Health, and the Veterans Health Administration during 2022 and 2023.
Significant Clinical Impact for High-Risk Patients
The research revealed that COVID-19 (搜索) boosters prevented one hospitalization or ICU admission for every 150-166 boosted cancer (搜索) patients. "The reduction in hospitalizations was significant, and the number of patients we needed to treat to see a benefit to the boosters is quite low," said Jane Figueiredo, PhD, director of Community Health and Population Research at Cedars-Sinai and senior author of the study.
Both the original monovalent booster (搜索) and the updated bivalent booster (搜索) targeting multiple COVID-19 (搜索) strains showed similar effectiveness in reducing hospitalizations by nearly 30 percent. When compared to people without compromised immune systems, cancer (搜索) patients showed similar percentage reductions in hospitalizations, but required fewer vaccinations to prevent a single hospitalization.
Low Booster Uptake Despite Proven Benefits
Despite the demonstrated effectiveness, the study revealed concerning trends in vaccination rates among cancer (搜索) patients. By January 1, 2022, only 68% of cancer patients had received a booster shot. The uptake was even lower for the updated bivalent boosters, with only 38% of patients receiving them after they became available.
"Whether this is due to patient concerns about safety or provider uncertainty about whether to administer a vaccine during treatment is not clear," Figueiredo noted. "What is clear is that we need to advocate strongly for vulnerable groups, including cancer (搜索) patients, to receive these vaccines."
Supporting Evidence for Current Guidelines
The findings provide crucial real-world evidence supporting major health organizations' recommendations for COVID-19 (搜索) vaccination in cancer (搜索) patients. "Cancer patients are a vulnerable population. Their immune systems can be weakened by their disease and the treatments they receive, which is why major health organizations recommend that these patients be vaccinated against COVID-19," Figueiredo explained.
James M. Crawford, MD, PhD, professor in the Institute of Health System Sciences at the Feinstein Institutes and co-principal investigator of the study, emphasized the clinical significance: "COVID-19 (搜索) vaccines can offer another layer of protection for individuals navigating cancer (搜索) treatment. This research provides critical information for doctors and patients making decisions about COVID-19 vaccination, especially for vulnerable groups."
Implications for Clinical Practice
Robert Figlin, MD, interim director of Cedars-Sinai Cancer (搜索), highlighted the study's importance: "This is the largest study to date of COVID-19 (搜索) booster effectiveness in cancer patients, a high-risk population of critical importance. It adds substantially to our understanding of the effectiveness of COVID-19 vaccines."
The research team plans to continue investigating vaccine effectiveness as new formulations become available and variants emerge. Figueiredo's team is also preparing to publish vaccine effectiveness data on patients with autoimmune diseases and solid organ transplant recipients, expanding understanding of how these vaccines work across different immunocompromised populations.
The study's findings underscore the importance of vaccination discussions between cancer (搜索) patients and their healthcare providers, particularly given the substantial protection offered by booster shots in preventing severe COVID-19 (搜索) outcomes in this high-risk population.